The present disclosure provides compounds and methods for inhibiting or degrading the N-terminal domain of the androgen receptor, as well as methods for treating cancers such as prostate cancer.

Disclosed herein are compounds and methods of using such compounds for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging, or for modulating one or more energy biomarkers, normalizing one or more energy biomarkers, or enhancing one or more energy biomarkers, wherein the compounds are tocopherol quinone derivatives. Further disclosed are compounds, compositions, and methods for treatment of, or prophylaxis against, radiation exposure.

Disclosed herein are compounds and methods of using such compounds for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging, or for modulating one or more energy biomarkers, normalizing one or more energy biomarkers, or enhancing one or more energy biomarkers, wherein the compounds are tocopherol quinone derivatives. Further disclosed are compounds, compositions, and methods for treatment of, or prophylaxis against, radiation exposure.

The present disclosure provides compounds and methods for inhibiting or degrading the N-terminal domain of the androgen receptor, as well as methods for treating cancers such as prostate cancer.

Compounds, such as cathinone derivatives, and pharmaceutical formulations that include the compounds. The compounds may have a first selectivity for a first receptor subtype that is at least 10 times greater than a second selectivity for a second receptor subtype from the same class of receptors. Methods of treating patients, which may include administering to a patient a pharmaceutical formulation that includes a compound, such as a cathinone derivative.

The invention relates to dioxomolybdenum (VI) complex compounds of the formula MoO.sub.2(L).sub.x(Y).sub.2-x, where the ligand L has the formula (I). Such complex compounds are suitable in particular as catalysts for one- and two-component polyurethane compositions. The invention also relates to two-component polyurethane compositions including at least one polyisocyanate as the first component, at least one polyol as the second component, and at least one such dioxomolybdenum (VI) complex compound as the catalyst. The invention further relates to one-component polyurethane compositions comprising at least one polyurethane prepolymer with isocyanate groups, which are made from at least one polyisocyanate with at least one polyol, and comprising such a dioxomolybdenum (VI) complex compound as the catalyst. The invention additionally relates to different uses of said polyurethane compositions. ##STR00001##

The invention relates to dioxomolybdenum (VI) complex compounds of the formula MoO.sub.2(L).sub.x(Y).sub.2-x, where the ligand L has the formula (I). Such complex compounds are suitable in particular as catalysts for one- and two-component polyurethane compositions. The invention also relates to two-component polyurethane compositions including at least one polyisocyanate as the first component, at least one polyol as the second component, and at least one such dioxomolybdenum (VI) complex compound as the catalyst. The invention further relates to one-component polyurethane compositions comprising at least one polyurethane prepolymer with isocyanate groups, which are made from at least one polyisocyanate with at least one polyol, and comprising such a dioxomolybdenum (VI) complex compound as the catalyst. The invention additionally relates to different uses of said polyurethane compositions. ##STR00001##

An AdipoR activator for activating both AdipoR1 and AdipoR2 is provided. A compound represented by the following formula (1), wherein A is a substituted or unsubstituted aryl group or the like, Y.sup.1 is (CHR.sup.2).sub.a— or the like, X is CH or N, R.sup.1 is a C.sub.1-7 alkyl group, m is an integer of 0-4, Y.sup.2 is *—O—CH.sub.2—CONH—, *—CONH—(CH.sub.2).sub.b—CO— or the like, Z is a cyclic group, B may be a substituent of the cyclic group represented by Z, and n is an integer of 0-3.

##STR00001##

An AdipoR activator for activating both AdipoR1 and AdipoR2 is provided. A compound represented by the following formula (1), wherein A is a substituted or unsubstituted aryl group or the like, Y.sup.1 is (CHR.sup.2).sub.a— or the like, X is CH or N, R.sup.1 is a C.sub.1-7 alkyl group, m is an integer of 0-4, Y.sup.2 is *—O—CH.sub.2—CONH—, *—CONH—(CH.sub.2).sub.b—CO— or the like, Z is a cyclic group, B may be a substituent of the cyclic group represented by Z, and n is an integer of 0-3.

##STR00001##

The present invention relates to novel compounds as HIF-1α inhibitors, manufacturing process thereof, and a pharmaceutical compositions. The compounds according to the present invention having inhibition activity against HIF-1α, can be used as a therapeutic prevention and/or treatment for various solid cancers such as colon cancer, liver cancer, stomach cancer and breast cancer. Also, the compounds according to the present invention are useful in the treatment of diabetic retinopathy and rheumatoid arthritis, which are aggravated by HIF-1α-mediated VEGFA expression.